PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC
NCT04284202
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
30
Enrollment
OTHER
Sponsor class
Conditions
NSCLC Stage IV
ARID1A
PD-1
Interventions
DRUG:
PD-1 plus Dasatinib
Sponsor
The Affiliated Hospital of Qingdao University